3 September 2026
Lenacapavir HIV prevention could accelerate South Africa’s epidemic control, but severe supply constraints are limiting the rollout.
5 August 2026
Lenacapavir production moves closer in SA as three local pharmaceutical manufacturers are shortlisted to produce the HIV-prevention injection.
3 August 2026
Older adults with HIV will nearly double by 2040. South Africa faces one of the sharpest rises, straining health systems.
29 June 2026
Lenacapavir HIV prevention offers twice-yearly PrEP, but trust, access, stigma and continued engagement will determine its impact.
12 June 2026
The Lenacapavir PrEP Rollout offers six-month HIV protection, but aid cuts and clinic access gaps raise concerns for high-risk groups.
7 February 2026
South Africa launches the HIV vaccine trial, BRILLIANT 01, testing a new vaccine cocktail designed to prime broadly neutralising antibodies.
9 January 2026
HIV prevention in South Africa hinges on local drug manufacturing to ensure access, reduce delays, and enable regional health security.
30 December 2025
Learn how long-acting injectable PrEP can transform HIV responses in South Africa while bridging treatment access gaps.
5 November 2025
Lenacapavir has been registered by SAHPRA as an innovative HIV prevention injection. Find out more about its rollout in South Africa.
30 September 2025
Explore the urgent call for lenacapavir access, as advocates seek equitable HIV prevention for all communities worldwide.
29 September 2025
Explore the benefits of the generic HIV prevention drug lenacapavir, set to change the landscape of global health by 2027.
5 September 2025
Gilead’s Lenacapavir is set to revolutionise HIV prevention efforts, aiming to protect two million people across affected nations.